Core Viewpoint - The company plans to invest up to 300 million yuan in Shanghai Haihe Pharmaceutical Research and Development Co., Ltd. through a share placement, indicating a strategic financial investment in the long-term potential of innovative drugs [1][2] Group 1: Investment Details - The company intends to subscribe for no more than 63,157,895 new shares of Haihe Pharmaceutical at a price of 4.75 yuan per share [1] - Post-investment, the company's shareholding in Haihe Pharmaceutical is expected to be between 5% and 8.09% [1] Group 2: Target Company Overview - Haihe Pharmaceutical focuses on the discovery, development, production, and commercialization of innovative drugs, particularly in the oncology field [1] - The company has developed over ten research pipelines, with three products already launched in China and Japan, and five products currently in clinical research [1] - Haihe Pharmaceutical's pipelines target various cancers and chronic diseases, aiming to meet unmet clinical needs [1] Group 3: Strategic Intent - The investment is aimed at ensuring stable operations of the main business while seeking reasonable financial returns and exploring opportunities in emerging industries [2]

Group 1 - The company announced that its 38th meeting of the 7th board of directors was held on August 10, 2025, through a combination of on-site and communication voting [2] - The meeting reviewed the proposal regarding cash capital increase in Shanghai Haihe Pharmaceutical Research and Development Co., Ltd. and related transactions [2]

Core Viewpoint - The audit report for Shanghai Haihe Pharmaceutical Research and Development Co., Ltd. indicates that the financial statements fairly reflect the company's financial position and operating results for the periods ending December 31, 2024, and February 28, 2025, in accordance with accounting standards [3][4]. Financial Performance - The company's operating revenue for the year 2024 and the first two months of 2025 was reported at RMB 32,267.25 million, with growth rates of 80.89% and 89.24% respectively [4][5]. Audit Opinion - The audit firm, Zhongxinghua Certified Public Accountants LLP, concluded that the financial statements are prepared in accordance with the relevant accounting standards and provide a true and fair view of the company's financial status [3][4]. Key Audit Matters - Revenue recognition was identified as a key audit matter due to its significance in the financial statements and the inherent risk of management manipulating revenue recognition to meet specific targets [4][5]. - The audit procedures included evaluating internal controls related to revenue recognition, sampling sales contracts, and verifying supporting documents such as invoices and payment receipts [5][6]. Management Responsibilities - The management of Haihe Pharmaceutical is responsible for preparing the financial statements in accordance with accounting standards and ensuring the effectiveness of internal controls to prevent material misstatements due to fraud or error [6][7]. Shareholder Structure - The company underwent several changes in its shareholder structure, with the latest registered capital amounting to RMB 718,243.65 million, reflecting the contributions from various investors [21][22].

Group 1 - The company approved a cash increase of up to RMB 300 million to participate in the financing of Shanghai Haihe Pharmaceutical Research and Development Co., Ltd. [1][2] - The company plans to acquire no less than 5% and no more than 8.09% of the equity in Haihe Pharmaceutical after the financing is completed [1][2] - The company will subscribe to a maximum of 63.157895 million new shares at a price of RMB 4.75 per share [1][2] Group 2 - The company will sign a subscription agreement with Haihe Pharmaceutical and related parties, which requires approval from the shareholders' meeting [2] - The board of directors and management are authorized to sign supplementary agreements regarding specific subscription amounts and quantities after the subscription agreement takes effect [2]

Core Viewpoint - The company has approved a cash increase investment in Shanghai Haihe Pharmaceutical Research and Development Co., Ltd. with a total amount not exceeding RMB 300 million, aiming to acquire a stake of at least 5% in the company after the financing completion [1][2]. Group 1 - The board meeting was held on August 10, 2025, with all 8 directors present, and the procedures complied with relevant regulations [1]. - The company plans to subscribe for new shares at a price of RMB 4.75 per share, potentially acquiring up to 63.157895 million shares [1][2]. - After the completion of the financing, the company's stake in Haihe Pharmaceutical is expected to be between 5% and 8.09% [1]. Group 2 - The company will sign a subscription agreement with Haihe Pharmaceutical and related parties, which requires approval from the shareholders' meeting [2]. - An independent director meeting was held prior to the board meeting, where the proposal was unanimously approved [2]. - The proposal will be submitted to the shareholders' meeting for further approval [2].

Core Viewpoint - The company plans to invest up to RMB 300 million in Shanghai Haihe Pharmaceutical Research and Development Co., Ltd. through a share subscription, aiming to hold at least 5% of the company's equity post-financing [1][3][27] Group 1: Transaction Overview - The share subscription price is set at RMB 4.75 per share, with a maximum subscription of 63.157895 million shares [1][3] - The financing plan involves a rights issue where existing shareholders can subscribe for new shares at a ratio of 2 shares for every 10 shares held [2][19] - The transaction constitutes a related party transaction due to the company's relationship with the controlling shareholder, Shanghai Nanjing Group [1][4] Group 2: Financial and Valuation Aspects - The estimated value of Haihe Pharmaceutical's total equity ranges from RMB 3.41 billion to RMB 4.01 billion based on asset-based valuation methods [20][21] - The company has a solid financial structure, with a low debt-to-asset ratio, indicating that the investment will not adversely affect its financial status [27] Group 3: Business and Market Context - Haihe Pharmaceutical focuses on innovative drug development in the oncology sector, with several products already commercialized or in advanced clinical stages [11][12] - The biopharmaceutical industry is a key growth area in Shanghai, supported by favorable policies and significant market potential [26][27] - The company has established a comprehensive R&D system and has multiple drug pipelines, indicating strong innovation capabilities [12][15]

证券代码：600503 证券简称：华丽家族 公告编号：临 2025-021 华丽家族股份有限公司 关于现金增资上海海和药物研究开发股份有限公司 暨关联交易的公告 本公司及董事会全体成员保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 1、华丽家族股份有限公司（以下简称"公司""上市公司""华丽家族"）拟 以总金额不超过人民币 3.00 亿元参与上海海和药物研究开发股份有限公司（以 下简称"海和药物""标的公司"）的配股融资（以下简称"本次增资""本次交 易"），且上市公司认购后持有标的公司的股权比例不低于海和药物配股融资完成 后总股本的 5%。根据海和药物的配股融资方案，公司拟作为海和药物股东上海 南江（集团）有限公司（以下简称" 南江集团"）的关联方，按每股价格 4.75 元认购海和药物新增股份不超过 6,315.7895 万股。上市公司最终认购数量及认购 金额将在标的公司董事会确定认购额度调配结果后最终确定。本次增资完成后， 预计上市公司持有海和药物配股融资完成后的股权比例不低于 5%、不高于 8.09%。 2、本次增资事项构成关 ...

目 录 上海海和药物研究开发股份有限公司 2024年度、2025年1-2月合并及母公司财务 报表 审计报告书 中兴华会计师事务所(特殊普通合伙) ZHONGXINGHUA CERTIFIED PUBLIC ACCOUNTANTS LLP 地址：北京市丰台区丽泽路 20 号丽泽 SOHO Ｂ座 20 层 邮编：100073 电话：(010) 51423818 传真：(010) 51423816 一、审计报告 三、审计报告附件 二、审计报告附送 1. 合并资产负债表 2. 合并利润表 3. 合并现金流量表 4. 合并股东权益变动表 5. 母公司资产负债表 6. 母公司利润表 7. 母公司现金流量表 8. 母公司股东权益变动表 9. 财务报表附注 1. 中兴华会计师事务所（特殊普通合伙）营业执照复印件 2. 中兴华会计师事务所（特殊普通合伙）执业证书复印件 3. 注册会计师执业证书复印件 中 兴 华 会 计 师 事 务 所 （ 特 殊 普 通 合 伙 ） Z H O N G X I N G H U A C E R T I F I E D P U B L I C A C C O U N T A N T S L L P ...

证券代码：600503 证券简称：华丽家族 公告编号：临2025-020 华丽家族股份有限公司 第七届监事会第二十七次会议决议公告 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性承法律责任。 华丽家族股份有限公司（以下简称 "公司"）第七届监事会第二十七次会议于 2025 年 8 月 10 日通过现场会议结合通讯表决的方式召开。会议通知于 2025 年 8 月 8 日以书面方式送达全体监事。本次会议应参加表决监事 3 人，实际参加表决监事 3 人。本次会议的召集、召开及表决程序符合《公司法》《公司章程》及《公司监事会 议事规则》等有关规定。会议由监事会主席陈俊女士主持，会议审议并通过了如下 议案： 一、审议并通过《关于现金增资上海海和药物研究开发股份有限公司暨关联交 易的议案》 同意公司拟以总金额不超过人民币3.00亿元参与上海海和药物研究开发股份有 限公司（以下简称"海和药物""标的公司"）的配股融资（以下简称"本次增资""本 次交易"），且上市公司认购后持有标的公司的股权比例不低于海和药物配股融资完 成后总股本的 5%。根据海和药物的配 ...

证券代码：600503 证券简称：华丽家族 公告编号：临2025－019 华丽家族股份有限公司 第七届董事会第三十八次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者 重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 华丽家族股份有限公司（以下简称 "公司"）第七届董事会第三十八次会议于2025 年8月10日通过现场会议结合通讯表决的方式召开。会议通知于2025年8月8日以书面方 式送达全体董事。会议由董事长王伟林先生主持，会议应参加表决董事8人，实际参加 表决董事8人，公司高级管理人员列席了会议。本次会议的召集、召开及表决程序符合 《公司法》《公司章程》及《公司董事会议事规则》等有关规定。经与会董事审议， 表决通过了如下议案： 一、审议并通过《关于现金增资上海海和药物研究开发股份有限公司暨关联交易 的议案》 同意公司拟以总金额不超过人民币 3.00 亿元参与上海海和药物研究开发股份有限 公司（以下简称"海和药物""标的公司"）的配股融资（以下简称"本次增资""本 次交易"），且上市公司认购后持有标的公司的股权比例不低于海和药物配股融资完 成后总股本的 5%。根据 ...